Qiming Venture Partners and Its Investors Named to 36Kr China Equity Investment Annual Lists
Time only rewards those who truly understand what they're doing.
Recently, 36Kr released its annual China Equity Investment Rankings and China's Top 100 Most Popular Investors Among Entrepreneurs. Qiming Venture Partners was named among the Top 5 VC firms in China's equity investment industry and the Top 10 Most Influential VC firms.
Duane Kuang, Founding Managing Partner; William Hu, Managing Partner; and Alex Zhou, Managing Partner of Qiming Venture Partners were all selected for the China's Top 100 Most Popular Investors Among Entrepreneurs list.
Qiming Venture Partners
Named
Top 5 VC Firm in China's Equity Investment Industry
Top 10 Most Influential VC Firm
Duane Kuang, Founding Managing Partner, Qiming Venture Partners
William Hu, Managing Partner, Qiming Venture Partners
Alex Zhou, Managing Partner, Qiming Venture Partners
Selected for
China's Top 100 Most Popular Investors Among Entrepreneurs
Selection Criteria
The rankings were determined through quantitative analysis across multiple dimensions, including assets under management, fundraising amounts, number of investment deals, and overall return levels. The evaluation period covered nearly four years of operational data, with the four core modules — fundraising, investment, management, and exit — weighted at 20%, 30%, 20%, and 30% respectively. The final results serve as an important reference for domestic investment institutions and innovative companies in investment, fundraising, and financing activities.
36Kr noted that the investment thesis in the venture capital industry has shifted over the past year. The narrative around artificial intelligence in the primary market has quietly undergone a change in logic. In 2025 alone, Embodied Artificial Intelligence attracted over 65.6 billion yuan in funding, with nearly a thousand companies entering the space. Looking further ahead, hard tech's share of VC investment has climbed from 38% to 62% over five years. There is no doubt that the center of gravity for capital is migrating downstream along the technology stack. AI is no longer just one of many sectors. It is cutting across the capillaries of virtually every industry in a manner that is almost irreversible. Time no longer automatically favors anyone — it only rewards those who truly understand what they are doing.
Source | 36Kr
Past Highlights
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 20, June 16, 2026
Qiming Honors | 5 Qiming Venture Partners Investors Named to 2025 Forbes China Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Arbutus Biopharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.